Case series report of presence of pruritus in five patients taking topiramate for treatment of epilepsy. This is a benign side effect of topiramate not previously reported that interfered with seizure treatment. Four out of five patients have previous history of antiepileptic drug (AED) allergy. Only one patient improved with a very slow titration, three of them discontinued treatment and one remained on a sub-therapeutic dose.
INTRODUCTION
Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug (AED). Topiramate also inhibits some isoenzymes of carbonic anhydrase (CA-II and CA-IV). This pharmacologic effect is generally weaker than that of acetazolamide, a known carbonic anhydrase inhibitor [3] [4] [5] . Paresthesia, an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of topiramate 3 . Rash occurred in more than 1% of adults treated with 200-400 mg of topiramate in placebo-controlled trials but with equal or greater frequency in the placebo group 5 . There are no previous reports of pruritus with use of topiramate.
MATERIALS AND METHODS
A retrospective case review of five patients with epilepsy who experienced pruritus after addition of topiramate to their anticonvulsant treatment.
History of previous allergies, concomitant medications, titration rate, and therapeutic strategies to control the side effects were analysed.
CASE #1
H.O. is a 47-year-old man with heterotopia and squizencephaly in the left parieto-occipital region and remote symptomatic seizures, refractory to medications. Topiramate dosing schedule: Initial titration by 25 mg every week up to 300 mg twice daily was well tolerated and produce partial improvement of seizure frequency. Further titration by 25 mg every week up to 700 mg a day was associated with intense pruritus without visible skin rash. Tapered down to 400 mg a day resolved the symptoms. Outcome: Partial seizure frequency reduction with a maximum dose tolerated 400 mg a day due to pruritus at higher doses.
